Effects of simvastatin on lipid profile, atherogenic index and serum transaminases in hyperlipidemic patients

Hyperlipidemia is characterized by increased concentrations of iipids including triglycerides, total cholesterol, low density lipoproteins, very low density lipoproteins in the blood and some times decreased high density lipoproteins. Many drugs have been used for treatment of this disorder. The present study was designed to estimate the effects of simvastatin on lipid profile, atherogenic index, transaminases, creatinine, uric acid and alkaline phosphatase. This study covered 70 subjects, they were divided into two groups, the first group included 45 hyperlipidaemic patients which were treated with 20mg simvastatin and second group included 25 normal subjects. After 12 hours fasting, serum lipid profile, transaminases; alkaline phosphatase, uric acid and creatinine were measured for the patients in 3 intervals before treatment, after 8 weeks and 16 weeks of treatment, and one time for normal subjects. After therapy, simvastatin showed a significant reduction in serum [TC, TG, LDL, VLDL and atherogenic index] and also, significant rise in HDL noticed, by performing a comparison between the group before treatment, and groups after treatment.Serum ALT, AST and ALP were significantly increased but were still within normal levels.Insignificant effect was observed from serum creatinine, uric acid and also body mass index by performing a comparison between group before treatment and groups after treatment. Conclusions:Simvastatin was effective in controlling lipid profile and atherogenic index, with no significant abnormality in liver functions

Effect of atorvastatin, with or without ezetimibe, on serum lipid profile and ALT in hyperlipidemic patients

Hyperlipidaemia is raised serum levels of one or more of total cholesterol, low-density lipoprotein and triglycerides. Many drugs have been used for the treatment of this disorder. This work compares the effects of atorvastatin with or without ezetimibe on lipid profile, atherogenic index and serum alanine aminotransferase. This study covers 90 subjects, 60 untreated hyperlipidemic patients, and 30 healthy subjects. Patients were divided into 2 groups, the first group included 30 patients treated with atorvastatin 20 mg/day alone, the second group included 30 patients treated with a combination of 2 drugs [atorvastatin 10 mg plus ezetimibe 10 mg] taken daily at night. Serum lipid profile, atherogenic index and serum alanine amniotransferase were measured after 12 hours fasting for the patients in 3 intervals: before, and after 8 weeks and 16 weeks of treatment. After therapy for both groups of patients, as compared to the levels before treatment, has shown that serum total cholesterol, triglycerides, low density lipoprotein cholesterol and very low density lipoprotein cholesterol were significantly reduced while high density lipoprotein cholesterol was significantly increased. Serum alanine aminotransferase increased by both groups of treatment with no significant difference between the two modes of treatment which has the same findings in comparison to the control group. Combination of atorvastatin 10 mg and ezetimibe 10 mg daily, is more effective than atorvastatin 20 mg taken alone